BioCardia Announces Pricing of Up To $12 Million Public Offering

Group 1 - BioCardia, Inc. announced a public offering of 4,800,000 shares of common stock and short-term warrants at a combined price of $1.25 per share [1][3] - The gross proceeds from the offering are expected to be $6 million, with an additional potential $6 million from the exercise of short-term warrants [3] - The company plans to use the net proceeds for working capital and general corporate purposes, including advancing investigational biotherapeutic candidates [3][6] Group 2 - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2] - The offering is being conducted under a registration statement on Form S-1, which was declared effective by the SEC on September 18, 2025 [4] - BioCardia is a leader in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with three clinical stage product candidates in development [6]